Abbott to cease sale of infant probiotic products after FDA warning
Send a link to a friend
[October 27, 2023]
(Reuters) -Abbott Laboratories will stop sales of its Similac
Probiotic Tri-Blend product used for hospitalized preterm infants after
the U.S. Food and Drug Administration issued a warning letter, the
health regulator said on Thursday.
In the letter, the FDA said it was concerned that preterm infants were
at risk of potentially fatal diseases or infections caused by bacteria
or yeast contained in the probiotics.
"The product is an unapproved new drug and an unlicensed biological
product being sold in violation" of regulations, the FDA said on
Thursday about Abbott's Similac probiotic product.
An Abbott spokesperson said the issue pertains to Similac Probiotic
Tri-Blend, which is used by fewer than 200 hospitals, and that it does
not apply to any of the company's infant formula products available at
retail stores.
The agency issued a similar warning to California-based Infinant Health
in September.
Infinant's product, sold under the brand Evivo with MCT Oil, has since
been voluntarily recalled and is no longer available in the country, the
FDA said.
Infinant did not immediately respond to a Reuters request for comment.
[to top of second column]
|
Abbott Laboratories logo is displayed on a screen at the New York
Stock Exchange (NYSE) in New York City, U.S., October 18, 2021.
REUTERS/Brendan McDermid/File Photo
In 2023, an infant death was
reported, and so far more than two dozen other adverse events
associated with probiotic products have been reported in the U.S.
since 2018, the agency said.
The FDA is also investigating reports that these products may have
contributed to additional adverse events, including death, and is
working to obtain the evidence and medical records.
Certain probiotic products used in hospital settings to prevent a
life-threatening bacterial illness have contributed to invasive
diseases, the agency said.
The warning letter is different to the baby formula issue of last
year, FDA said, referring to the closure of Abbott's plant in
Michigan following a recall of some products due to bacterial
contamination.
(Reporting by Leroy Leo and Khushi Mandowara in Bengaluru; Editing
by Shinjini Ganguli and Sriraj Kalluvila)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |